Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference

They’re doing a lot of presenting, but not a lot of releasing of iti-007 :smile:

1 Like

The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression.

So, this won’t be helpful to mania?

They’re only talking about bipolar depression at the moment. But that doesn’t make sense in a way. Bipolar implies mania.

You’re right I’m being dumb. Nevermind me

isn’t bipolar remix of maniac and depressive phase…
cuz i am szaff…

You’re not being dumb at all. It’s worrying that they’re only concentrating on that. Maybe it’s for commercial / getting approved reasons.

1 Like

Minnii, I think you’re right unfortunately.

ITI-007 for the Treatment of Depressive Episodes Associated with Bipolar Disorder (Bipolar Depression)

It may be no good for mania on its own.

Damn, I knew it was too good to be true. They also say it’s effective against schizoaffective, so there’s still hope. My guess is that is stimulating, so I think my pdoc won’t be very happy about it. He is very against anything that is stimulating for me.

The only side effect is mild sedation in fact.

There due any day now to release their clinical trial information. It has been about 6 months.